Primary aldosteronism (PA) is a potentially curable form of secondary hypertension, but is regarded as being relatively rare in unselected hypertensive populations. The prevalence and characteristics of PA were evaluated on 1046 subsequent hypertensive patients (pts) sent to a referral Hypertension Center between January 1 st 1997 and December 31 st 1999. Screening of PA was performed with the captopril test. Final diagnosis was based on lack of suppression of aldosterone upon acute volume expansion. Aldosteronoma (A) was defined as a unilateral adrenal nodule on CT scan with enhanced uptake at 131 I-cholesterol scintigraphy. The diagnosis of idiopathic hyperaldosteronism (IHA) was based on evidence of bilateral adrenal hyperplasia on CT scan and enhanced bilateral uptake at scintigraphy. Sixty-six (6.3%) pts were finally diagnosed as having PA. In 16 (24.2%) of these pts, A was demonstrated by adrenal CT and scintigraphy, and the diagnosis histologically confirmed in the 10 cases so far submitted to surgery. In the remaining 50 (75.8%) pts IHA was diagnosed. 668, Pϭ0.197). We conclude that: 1) PA is more frequent than traditionally thought; 2) it is not necessarily associated with severe and/or resistant hypertension; 3) IHA seems to be more prevalent than A; 4) hypokalemia is not a sensitive criterion for the screening of PA. The aim of this study was to show how the adjunction of Spironolactone(Spi) to the treatment of refractory hypertensive patients (RH) might permit an optimal blood pressure (BP) control.
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Methods : Among all the 520 patients who have been referred for treatment of hypertension in a medical clinic from 1997 to 1999, 25 patients had refractory hypertension. The inclusion criteria were 1) hypertension of at least six months without any apparent cause 2)clinical BP above 140/90 mm Hg in spite of at least two antihypertensive drugs (AT) given at optimal dosage 3) no previous use of Spi 4) proper 24 hours ambulatory blood pressure monitoring (ABPM) showing an average BP above 140/90 mm Hg.Potassium and serum creatinine were checked before the introduction of Spi and one month after. In case of renal insufficiency (creatinine above 15 mg/l) patients were excluded from the treatment by Spi.If patients were on Angiotensin Converting Enzyme inhibitor (ACE), this drug was replaced by Spi at a dosage of 1 mg/kg. Otherwise, Spi was added to the previous treatment at the same dosage.
Results :After one month of treatment by Spi, 23 patients had a clinical BP below 140/90 mm Hg. On the whole population of RH patients, ABPM showed a significant decrease in both systolic (151.6 Ϯ1.8 mm Hg to 128.6.Ϯ2 mm Hg pϽ0.001) and diastolic pressure (85.7 Ϯ 1.8 mm Hg to 77.6 Ϯ 1.8 mm Hg pϽ0.013). Three months after introduction of Spi, the decrease in the number of AT, which was made possible by the introduction of Spi, was highly significant (pϽ0.001). No biological side effect was observed. Two patients experienced clinical side effects. In these two cases, Spi was replaced by ACE, which turned out to be more effective after treatment by Spi than previously .
Conclusion Hypersecretion of Aldosterone may be underestimated in patients with RH. The use of Spi for these patients is safe, efficient and gives durable results, which leads to a simplification of the initial treatment. We have examined the early pathophysiologic and molecular events associated to the development of aldosterone-induced myocardial disease. Uninephrectomized, saline-drinking, Sprage-Dawley rats (250g, nϭ48) were fitted with osmotic mini-pumps containing either aldosterone (0.75 micro gr/hr, s.c., ALDO) or vehicle (VEH). Previous studies showed that this treatment induces myocardial hypertrophy and fibrosis after 6 to 8 weeks. Radio-telemetric determination of blood pressure over 28 days evidenced the progressive development of hypertension in ALDO-infused (systolic: 230 mmHg) vs. VEH-treated rats (systolic: 134 mmHg, PϽ.001). Six animals from each group were sacrificed after 3, 7, 14 or 28 days of infusion. Histopathologic examination of the hearts showed the presence of biventricular, perivascular inflammatory infiltrates in 4 of the 6 animals infused with aldosterone for 7 days and in all rats receiving ALDO for 14 or 28 days. The lesions compromised primarily medium and small-sized coronary arteries. The perivascular inflammatory cells were identified as mainly macrophages (ED1 staining) and were associated in some cases with fibrinoid necrosis of the media. Cardiomyocyte necrosis was observed only in areas of extensive vascular inflammation and progressed in frequency and severity with time. No lesions were observed in animals infused with either VEH or ALDO for only 3 days. Morphometric determination of interstitial collagen volume fraction or perivascular collagen did not show significant increases in response to ALDO treatment at these early time-points. Progressive pathophysiology was profiled using gene microarray analysis and over 500 genes demonstrated significant differential expression with ALDO compared to VEH. RT-PCR analysis demonstrated a statistically significant (PϽ.05) ALDO-induced upregulation of the expression of ANP (27.9-fold), BNP (3.0-fold), myosin heavy chain-␤ (3.7-fold), and endo-
